By Michael Erman
April 14 (Reuters) – Johnson & Johnson reported first-quarter earnings that beat Wall Street expectations on Tuesday and raised its full-year forecast, as robust demand for most cancers drug Darzalex and psoriasis therapy Tremfya greater than offset a steep falloff in sales of its blockbuster autoimmune drug Stelara.
The drug and gadget maker reported first-quarter income of $24.1 billion, up practically 10% from a yr earlier. That exceeded analysts’ estimates of $23.6 billion, in line with LSEG knowledge. Adjusted earnings got here in at $2.70 per share, above the consensus estimate of $2.66.
Stelara, which topped $10 billion in annual sales at its peak, is going through biosimilar competitors after shedding patent safety final yr. Sales of the drug fell round 60% from a yr in the past to $656 million.
Shares of the corporate, which have risen 15% to this point this yr, had been marginally down premarket.
Chief Financial Officer Joseph Wolk stated in an interview that as an alternative of switching to the biosimilars, many sufferers have chosen different therapies like Tremfya.
“We are seeing increased share in Tremfya and we anticipate we’ll see something similar in the new oral offering,” Wolk stated, referring to its new drug Icotyde, which was permitted in March.
Tremfya, which treats psoriasis as properly as inflammatory bowel ailments, introduced in $1.6 billion for the quarter. Analysts had been anticipating sales of $1.2 billion for the drug.
Sales of Darzalex, a blood most cancers remedy launched in 2015, had been $4.0 billion for the quarter, simply beating analysts’ expectations of $3.4 billion.
Quarterly sales for the medical expertise enterprise rose 7.7% to $8.6 billion, consistent with analysts’ expectations. The firm raised its full-year 2026 income forecast vary with a brand new midpoint of about $100.8 billion, simply above Wall Street’s estimate of $100.6 billion. It additionally lifted its adjusted earnings outlook to $11.55 per share on the midpoint, about in line with present expectations.
J&J is among the many group of prime world drugmakers which have agreed to so-called most-favored-nation drug pricing offers with the Trump administration. The firms have stated they may decrease their U.S. drug costs to match these charged in different developed international locations, in change for tariff aid.
President Donald Trump has requested for Congress to codify the most-favored-nation offers by means of laws, however Wolk stated J&J believes that will be dangerous coverage.
“We’re not a fan of codifying” MFN, he stated. “It’s really kind of a back door to price controls and we’ve seen what happens in countries with price controls – patients have less access to the most important medicines and innovation goes down.”
(Reporting by Michael Erman in New Jersey; Additional reporting by Kamal Choudhury and Mrinalika Roy in Bengaluru; Editing by Bill Berkrot)
